Clinical analysis of the complex endocrine treatment for the elderly with prostate cancer at middle and late stages
10.3760/cma.j.issn.0254-9026.2011.12.010
- VernacularTitle:老年中晚期前列腺癌患者内分泌综合治疗临床分析
- Author:
Shaoyong WANG
;
Haiqun LIN
;
Bo SHU
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Androgens;
Withholding treatment;
Orchiectomy
- From:
Chinese Journal of Geriatrics
2011;30(12):1015-1017
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the clinical effects of androgen blockade combined treatment for the elderly with middle and late prostate cancer.Methods 63 patients (average age of 69.3 years) with middle and late prostate cancer (above stage T3 ) were studied retrospectively from June 2001 to August 2009.21 cases were treated by operation of bilateral orchidectomy independently.15 cases were treated by castration independently (enantone 3.75 mg or zoladex 3.6 mg/month,hypodermic injection for one year).27 cases were treated by bilateral orchidectomy plus maximum androgen blockade (MAB) (bicalutamide 50 mg,qd,fulutimad 250 mg,rid,po.)Results The survival rates of 1,2,3 years were 100.0％,90.0％,75.0％ in operation group,100.0％,86.7 ％,73.3％ in drug group,and 100.0％,96.2％,84.6％ in MAB group,respectively.The survival rates of 3 years was higher in MAB group than the other groups(x2 =4.460,P＜0.05).The levels of PSA within 3 months decreased and urinary flow rates in three groups increased after treatment than before treatment (t =2.641,3.074,6.703,P ＜ 0.01 ) with no differences among the groups.The relieve period of validity was longer in MAB group than in other groups (F=16.57,P＜0.01 ).Conclusions MAB may be more effective for the elderly with middle and late prostate cancer than castration therapy independently.
